These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2404906)
41. Erythrocyte polyamine determinations in patients with head and neck cancer. Shideler CE; Johns ME; Cantrell RW; Shipe JR; Wills MR; Savory J Arch Otolaryngol; 1981 Dec; 107(12):752-4. PubMed ID: 7316857 [TBL] [Abstract][Full Text] [Related]
42. Immunosuppressive substance in the sera of head and neck cancer patients. Yamanaka N; Harabuchi Y; Himi T; Kataura A Cancer; 1988 Oct; 62(7):1293-8. PubMed ID: 3416271 [TBL] [Abstract][Full Text] [Related]
43. Adenosine deaminase, xanthine oxidase, superoxide dismutase, glutathione peroxidase activities and malondialdehyde levels in the sera of patients with head and neck carcinoma. Kalcioğlu MT; Kizilay A; Yilmaz HR; Uz E; Güleç M; Ozturan O; Akyol O Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):16-22. PubMed ID: 16010092 [TBL] [Abstract][Full Text] [Related]
44. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105 [TBL] [Abstract][Full Text] [Related]
45. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Engarås B Dis Colon Rectum; 2003 Mar; 46(3):313-21. PubMed ID: 12626905 [TBL] [Abstract][Full Text] [Related]
46. Detection of five circulating antigens in patients with head and neck squamous cell carcinoma. Screm MC; Grandis S; Cartei G; Cattaruzzi E Int J Biol Markers; 1989; 4(1):35-9. PubMed ID: 2501400 [TBL] [Abstract][Full Text] [Related]
47. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer. Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of glycoproteins as prognosticators in head and neck malignancy. Bathi RJ; Nandimath K; Kannan N; Shetty P Indian J Dent Res; 2001; 12(2):93-9. PubMed ID: 11665403 [TBL] [Abstract][Full Text] [Related]
49. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
50. Objective measurement of therapeutic response in breast cancer using tumour markers. Robertson JF; Pearson D; Price MR; Selby C; Blamey RW; Howell A Br J Cancer; 1991 Oct; 64(4):757-63. PubMed ID: 1911226 [TBL] [Abstract][Full Text] [Related]
51. TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. Filella X; Fuster J; Molina R; Grau JJ; García-Valdecasas JC; Grande L; Estapé J; Ballesta AM Acta Oncol; 1994; 33(7):747-51. PubMed ID: 7993641 [TBL] [Abstract][Full Text] [Related]
52. Early diagnosis of radiotherapy failure for patients with head and neck cancer: the role of biochemical markers. Mrochem-Kwarciak J; Rutkowski T; Wygoda A; Deja R; Hajduk A; Składowski K Tumori; 2018 Aug; 104(4):273-279. PubMed ID: 28604997 [TBL] [Abstract][Full Text] [Related]
53. [Clinical value of head and neck tumor markers]. Gascón Vilaplana P Med Clin (Barc); 2007 Dec; 129(20):775-6. PubMed ID: 18093479 [No Abstract] [Full Text] [Related]
54. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients. Paulick R; Caffier H; Paulick M Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016 [TBL] [Abstract][Full Text] [Related]
55. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816 [TBL] [Abstract][Full Text] [Related]
56. Elevated carcinoembryonic antigen tumour marker caused by head and neck cancer: a case report and literature study. Vingerhoedt SI; Hauben E; Hermans R; Vander Poorten VL; Nuyts S Cancer Radiother; 2015 Apr; 19(2):106-10. PubMed ID: 25457791 [TBL] [Abstract][Full Text] [Related]
57. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Xi L; Nicastri DG; El-Hefnawy T; Hughes SJ; Luketich JD; Godfrey TE Clin Chem; 2007 Jul; 53(7):1206-15. PubMed ID: 17525108 [TBL] [Abstract][Full Text] [Related]
58. Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients. Li SX; Yang YQ; Jin LJ; Cai ZG; Sun Z Cancer Biomark; 2016; 17(4):377-382. PubMed ID: 27662323 [TBL] [Abstract][Full Text] [Related]
59. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers. Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555 [TBL] [Abstract][Full Text] [Related]
60. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer. Knychalski B; Lukieńczuk T Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]